TreatSMA Rare Disease Day event EXCLUSIVE – This Saturday, 29th February, don’t miss it!

As we published earlier in the week TreatSMA is proud to be supporting the Royal Holloway’s 10th Annual Rare Disease Day Event on Wednesday 26th in support of Rare Disease Day. However, the excitement doesn’t stop there.

We have two amazing things happening on Rare Disease Day this Saturday, 29th February. Firstly, in the morning we will be presenting a video from treatSMA trustee, Kelly and her son Vinnie, showing what a day looks like for them managing SMA.

The second event is an exclusive webinar where we are fortunate enough to have representatives from a number of rare conditions talking about the condition, how it affects them and their families. While we fight for SMA it’s important to note that we, as part of the rare disease community, have to support each other to ensure our voices are heard. This is a great opportunity for all organisations to do something jointly and to help get our message out.

Posters of the events can be accessed below, they have all the appropriate information, please do share as much as you can.

 

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more